 Marsha Anderson
Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 19 | 2025 | 91 | 2.590 |
Why?
| | Immunoglobulins, Intravenous | 6 | 2020 | 126 | 0.580 |
Why?
| | Infliximab | 3 | 2019 | 110 | 0.390 |
Why?
| | Internship and Residency | 3 | 2023 | 1157 | 0.240 |
Why?
| | Diagnostic Errors | 2 | 2008 | 171 | 0.230 |
Why?
| | Pediatrics | 4 | 2018 | 1061 | 0.230 |
Why?
| | Fever | 3 | 2020 | 304 | 0.220 |
Why?
| | Coronary Aneurysm | 2 | 2019 | 14 | 0.220 |
Why?
| | Benzazepines | 1 | 2004 | 36 | 0.220 |
Why?
| | Child, Preschool | 19 | 2025 | 10952 | 0.210 |
Why?
| | Nasopharynx | 3 | 2015 | 73 | 0.200 |
Why?
| | Coronary Vessels | 3 | 2018 | 243 | 0.200 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 229 | 0.190 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2004 | 314 | 0.190 |
Why?
| | Infant | 15 | 2025 | 9392 | 0.180 |
Why?
| | Child | 18 | 2025 | 21760 | 0.170 |
Why?
| | Circulating MicroRNA | 1 | 2020 | 24 | 0.160 |
Why?
| | Machine Learning | 1 | 2025 | 513 | 0.160 |
Why?
| | Climate Change | 1 | 2021 | 184 | 0.150 |
Why?
| | Steroids | 1 | 2019 | 157 | 0.150 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 483 | 0.150 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 110 | 0.140 |
Why?
| | Neutrophils | 1 | 2004 | 1264 | 0.140 |
Why?
| | Respiratory Tract Infections | 2 | 2015 | 384 | 0.140 |
Why?
| | Immunologic Factors | 1 | 2019 | 236 | 0.130 |
Why?
| | Faculty, Medical | 3 | 2018 | 287 | 0.130 |
Why?
| | Algorithms | 2 | 2025 | 1700 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 236 | 0.120 |
Why?
| | Career Choice | 1 | 2018 | 226 | 0.120 |
Why?
| | Calcitonin | 1 | 2015 | 27 | 0.120 |
Why?
| | Physician Executives | 2 | 2018 | 33 | 0.120 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 451 | 0.110 |
Why?
| | Immunoglobulins | 1 | 2015 | 168 | 0.110 |
Why?
| | Echocardiography, Doppler | 1 | 2015 | 108 | 0.110 |
Why?
| | Particulate Matter | 1 | 2016 | 316 | 0.100 |
Why?
| | Coronary Artery Disease | 3 | 2018 | 698 | 0.100 |
Why?
| | Rhinovirus | 2 | 2015 | 57 | 0.100 |
Why?
| | Humans | 28 | 2025 | 136965 | 0.100 |
Why?
| | Colorado | 8 | 2015 | 4542 | 0.100 |
Why?
| | Accreditation | 2 | 2023 | 84 | 0.090 |
Why?
| | Gastroenteritis | 1 | 2013 | 68 | 0.090 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2015 | 362 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1295 | 0.090 |
Why?
| | Treatment Failure | 1 | 2013 | 338 | 0.090 |
Why?
| | Disease Outbreaks | 2 | 2007 | 422 | 0.090 |
Why?
| | Environmental Exposure | 1 | 2016 | 573 | 0.090 |
Why?
| | Coronavirus | 2 | 2015 | 47 | 0.090 |
Why?
| | Program Development | 2 | 2018 | 367 | 0.090 |
Why?
| | Leadership | 2 | 2018 | 393 | 0.090 |
Why?
| | Male | 18 | 2025 | 67386 | 0.080 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1022 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 348 | 0.080 |
Why?
| | Aspirin | 1 | 2013 | 389 | 0.080 |
Why?
| | Female | 17 | 2025 | 73002 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2013 | 519 | 0.070 |
Why?
| | Enterovirus Infections | 2 | 2008 | 177 | 0.070 |
Why?
| | Picornaviridae Infections | 1 | 2008 | 50 | 0.070 |
Why?
| | Curriculum | 2 | 2021 | 998 | 0.070 |
Why?
| | Mentors | 1 | 2010 | 209 | 0.070 |
Why?
| | Liver Diseases | 1 | 2011 | 300 | 0.070 |
Why?
| | Enterovirus A, Human | 1 | 2007 | 13 | 0.070 |
Why?
| | Retrospective Studies | 8 | 2018 | 15536 | 0.070 |
Why?
| | HIV Infections | 1 | 2002 | 2898 | 0.070 |
Why?
| | Logistic Models | 2 | 2018 | 2066 | 0.060 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2008 | 232 | 0.060 |
Why?
| | Central Nervous System Viral Diseases | 1 | 2007 | 79 | 0.060 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 506 | 0.060 |
Why?
| | Virus Diseases | 1 | 2008 | 212 | 0.060 |
Why?
| | Diagnosis, Differential | 3 | 2020 | 1470 | 0.060 |
Why?
| | Antibodies, Monoclonal | 1 | 2013 | 1412 | 0.060 |
Why?
| | Medical Records | 2 | 2018 | 180 | 0.060 |
Why?
| | Education, Medical, Undergraduate | 1 | 2007 | 187 | 0.060 |
Why?
| | Medical Audit | 1 | 2005 | 76 | 0.060 |
Why?
| | Clinical Competence | 2 | 2023 | 1114 | 0.060 |
Why?
| | CD11b Antigen | 1 | 2004 | 62 | 0.050 |
Why?
| | Infectious Disease Medicine | 1 | 2023 | 12 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2005 | 236 | 0.050 |
Why?
| | Superoxides | 1 | 2004 | 217 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 279 | 0.050 |
Why?
| | Coronavirus Infections | 1 | 2006 | 365 | 0.040 |
Why?
| | United States | 4 | 2025 | 14945 | 0.040 |
Why?
| | Ultrasonography | 1 | 2005 | 761 | 0.040 |
Why?
| | Knowledge | 1 | 2021 | 56 | 0.040 |
Why?
| | Polymerase Chain Reaction | 3 | 2008 | 1045 | 0.040 |
Why?
| | Discriminant Analysis | 1 | 2020 | 37 | 0.040 |
Why?
| | Schools, Medical | 2 | 2014 | 149 | 0.040 |
Why?
| | Case-Control Studies | 3 | 2020 | 3556 | 0.040 |
Why?
| | Time Factors | 2 | 2016 | 6786 | 0.040 |
Why?
| | Health Resources | 1 | 2021 | 118 | 0.040 |
Why?
| | Risk Factors | 3 | 2018 | 10363 | 0.040 |
Why?
| | Infant, Newborn | 3 | 2019 | 6051 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 309 | 0.030 |
Why?
| | Education, Medical | 1 | 2021 | 269 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 749 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 783 | 0.030 |
Why?
| | Learning | 1 | 2021 | 412 | 0.030 |
Why?
| | Biomarkers | 2 | 2020 | 4095 | 0.030 |
Why?
| | Urban Health | 1 | 2016 | 96 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 615 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 2015 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2020 | 1923 | 0.030 |
Why?
| | Canada | 1 | 2016 | 407 | 0.030 |
Why?
| | Particle Size | 1 | 2016 | 391 | 0.030 |
Why?
| | Diastole | 1 | 2015 | 144 | 0.030 |
Why?
| | Risk Assessment | 2 | 2021 | 3446 | 0.030 |
Why?
| | Systole | 1 | 2015 | 182 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2005 | 1784 | 0.030 |
Why?
| | Adenoviridae | 1 | 2015 | 194 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 1999 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 547 | 0.030 |
Why?
| | Adolescent | 3 | 2019 | 21471 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2021 | 957 | 0.030 |
Why?
| | Exanthema | 1 | 2013 | 78 | 0.020 |
Why?
| | Health Surveys | 1 | 2014 | 523 | 0.020 |
Why?
| | Physicians | 1 | 2021 | 921 | 0.020 |
Why?
| | Needs Assessment | 1 | 2014 | 380 | 0.020 |
Why?
| | Abdominal Pain | 1 | 2013 | 146 | 0.020 |
Why?
| | Cohort Studies | 2 | 2018 | 5688 | 0.020 |
Why?
| | Incidence | 2 | 2012 | 2793 | 0.020 |
Why?
| | gamma-Glutamyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
| | Aspartate Aminotransferases | 1 | 2011 | 84 | 0.020 |
Why?
| | Bilirubin | 1 | 2011 | 88 | 0.020 |
Why?
| | Prevalence | 2 | 2008 | 2732 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2011 | 150 | 0.020 |
Why?
| | Societies, Medical | 1 | 2014 | 811 | 0.020 |
Why?
| | Echocardiography | 1 | 2012 | 639 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2015 | 836 | 0.020 |
Why?
| | Peer Group | 1 | 2010 | 244 | 0.020 |
Why?
| | Enterovirus | 1 | 2008 | 86 | 0.020 |
Why?
| | Meningitis, Aseptic | 1 | 2007 | 13 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2809 | 0.020 |
Why?
| | Virus Cultivation | 1 | 2007 | 31 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2831 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7512 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2013 | 779 | 0.020 |
Why?
| | Cerebrospinal Fluid | 1 | 2007 | 91 | 0.020 |
Why?
| | Paralysis | 1 | 2007 | 72 | 0.020 |
Why?
| | Multiple Organ Failure | 1 | 2007 | 123 | 0.020 |
Why?
| | Patient Admission | 1 | 2008 | 197 | 0.020 |
Why?
| | Prognosis | 1 | 2015 | 3931 | 0.020 |
Why?
| | Clinical Clerkship | 1 | 2007 | 103 | 0.020 |
Why?
| | Respiratory System | 1 | 2007 | 155 | 0.020 |
Why?
| | Encephalitis | 1 | 2007 | 135 | 0.010 |
Why?
| | Program Evaluation | 1 | 2010 | 907 | 0.010 |
Why?
| | Adult | 2 | 2014 | 37715 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 993 | 0.010 |
Why?
| | Gastrointestinal Tract | 1 | 2007 | 202 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2019 | 10664 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2007 | 824 | 0.010 |
Why?
| | RNA, Viral | 1 | 2006 | 682 | 0.010 |
Why?
| | Confidence Intervals | 1 | 2002 | 331 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2002 | 513 | 0.010 |
Why?
| | Reference Values | 1 | 2002 | 797 | 0.010 |
Why?
| | Odds Ratio | 1 | 2002 | 1071 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2002 | 1301 | 0.010 |
Why?
| | Urban Population | 1 | 2002 | 481 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 33226 | 0.010 |
Why?
|
|
Anderson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|